Keep the result with its context.

There is room for hope and for careful questions in the same conversation.

In SURMOUNT-1, adults without diabetes taking tirzepatide lost about 15% to 21% of their initial weight on average over 72 weeks.

The result depended on the amount of medicine in the study shot; the group given a placebo, a shot without the study drug, lost about 3%.

The medicine’s maker supported the study, which included regular visits and advice about food and physical activity.

An average is not a promise about your result. Ask what a useful goal and follow-up plan would look like for you.

In SURMOUNT-4, people first used tirzepatide for 36 weeks, then some switched to placebo.

Over the next 52 weeks, the people switched to placebo gained an average of 14% of the body weight they had at the end of the first 36 weeks.

The percentage uses their weight just before they stopped the drug. It does not mean a percentage of the pounds they had lost.

Those who continued tirzepatide lost a further average of 5.5% over that period.

This gives a reason to ask about the longer plan, including costs and any later change in treatment. It does not decide that plan for you.

Where to read the source behind a question

For rules about pharmacies making versions of drug-company medicines, use the FDA’s dated policy updates.

For the temporary Medicare program, use Medicare’s eligibility information.

Keep the source beside the claim you want to ask about. Mark the part that feels unclear and bring it to the conversation.

Take the part that matters to your next conversation.